Princeton, NJ / July 5, 2023 / Global Clinical Trials, a full-service CRO providing clinical research services since 2001, has announced operations to span into China. This strategic move opens a new region for GCT and its Clients and adds thousands of experienced sites and a diverse patient population. GCT now operates in over 20 countries, primarily across Europe, the United States, and Asia, and has gained recognition for its thoughtful approach to each trial.
China is the second biggest pharmaceutical market in the world. It is an attractive country for clinical trials due to its large pool of treatment-naïve patients and local experts. There have also been regulatory improvements recently – China’s National Medical Products Administration (NMPA) introduced updates to its review process. From IND to approval, the cycle takes only about 5 to 6 months. The timeline includes preparation and scheduling of a pre-IND meeting, and communication with NMPA before the submission continuing through to approval. There is also government support for international partnerships along with the improved regulatory environment for trials and new drug approvals.
With many established clinical trial sites employing expert teams, a robust network of experienced specialists, and advanced technologies in use, there is a sturdy foundation to support clinical trial operations successfully in China.
GCT has established strong relationships with the Chinese pharmaceutical market – we have been working on various studies with Chinese Pharma since 2018. Launching our operations in the region demonstrates the company’s dedication to expanding its reach, providing high-quality services, and taking on larger studies.
If you are planning on conducting a clinical trial in China, our team would be happy to answer your questions – please contact us at firstname.lastname@example.org.